Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphoma: experimental drug CHO-H01 enters human trials

NCT ID NCT05950165

Recruiting now Disease control Sponsor: Cho Pharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in low-grade lymphoma. Up to 37 participants will be monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology

    RECRUITING

    Kaohsiung City, 833, Taiwan

  • Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology

    TERMINATED

    Taoyuan, Taoyuan, 33305, Taiwan

  • Chi-Mei Medical Center

    RECRUITING

    Tainan, Taiwan, 71004, Taiwan

  • China Medical University Hospital - Hematology/Oncology - Taichung

    RECRUITING

    Taichung, 404, Taiwan

  • National Cheng Kung University Hospital - Internal Medicine

    TERMINATED

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital - Hematology And Oncology

    RECRUITING

    Taipei, 100, Taiwan

  • National Taiwan University Hospital Yunlin Branch

    RECRUITING

    Huwei, Taiwan, 632, Taiwan

  • Taipei Medical University - Shuang Ho Hospital - Oncology

    RECRUITING

    New Taipei City, Taipei Special Municipality, 23561, Taiwan

  • Tri-Service General Hospital - Neihu Branch - Hematology

    TERMINATED

    Taipei, Taipei, 11490, Taiwan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CHO-H01 (an experimental drug) and lenalidomide

What this could lead to

If successful, this could offer a new treatment option for people with hard-to-treat non-Hodgkin lymphoma that has not responded to other therapies.

What could go wrong

This is an early-phase trial with only 37 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA